In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …

Background Detection of the BRAF V600E mutation in pediatric low-grade glioma has been
associated with a lower response to standard chemotherapy. In previous trials, dabrafenib …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade
gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve …

Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and
have shown preliminary clinical activity against m IDH glioma. We evaluated both agents in …

Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …

Abstract Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy
is associated with short-and long-term toxicity. Progression to higher tumor grade is …

Summary Background The Response Assessment in Neuro-Oncology (RANO) criteria and
requirements for a uniform protocol have been introduced to standardise assessment of MRI …